Goodman A et al. GLANCE : Results of a phase 2 randomized double blind placebo controlled study. Neurology 2009; 72:806-812.
Study adding Tysabri to glatiramer-- safety trial. Results showed increased natalizumab antibodies, but safe otherwise. Efficacy was much better in combination group than in the GA alone group re MRI. 110 patients were randomized, half got GA + placebo, others GA + NAT. Took patients with active disease year before entry.
Study adding Tysabri to glatiramer-- safety trial. Results showed increased natalizumab antibodies, but safe otherwise. Efficacy was much better in combination group than in the GA alone group re MRI. 110 patients were randomized, half got GA + placebo, others GA + NAT. Took patients with active disease year before entry.
No comments:
Post a Comment